The objective of this observational study is to characterize the patient profile and nutritional treatment patterns of individuals with type 2 diabetes (T2D) or drug-induced diabetes who present with malnutrition, or are at risk of it, and who are prescribed a diabetes-specific oral nutritional supplement (ONS) that is high in calories and protein and contains soluble fiber. Participants will complete a series of questionnaires during visits 1 and 3.
1. Background and Rationale This study focuses on patients with type 2 diabetes mellitus (T2D) who also present with malnutrition or are at risk of developing malnutrition. These conditions negatively affect clinical and functional outcomes, increasing the likelihood of complications and hospitalizations. The use of diabetes-specific oral nutritional supplements (ONS)-characterized by a high caloric and protein content and enriched with soluble fiber-may contribute to improving clinical status, nutritional parameters, and quality of life. Nevertheless, current evidence from real-world clinical practice remains limited and heterogeneous. 2. Primary Objective To characterize the clinical and nutritional profile, as well as the nutritional treatment patterns, of patients with T2D and malnutrition or at risk of malnutrition who are prescribed a diabetes-specific ONS. 3. Secondary Objectives To assess changes in glycemic and metabolic control. To evaluate the nutritional and functional impact of the ONS. To analyze healthcare resource utilization and associated costs. To estimate patient adherence, compliance, and satisfaction with the prescribed ONS. To assess quality-of-life outcomes over a 6-month follow-up period. 4. Exploratory Objective To explore changes in muscle mass using nutritional ultrasound. 5. Study Design Multicenter, prospective, real-world evidence (RWE) study. Conducted across 12 hospitals in Spain. Three scheduled visits: baseline (V1), 3-month follow-up (V2), and 6-month final visit (V3). 6. Study Population A total of 334 adult patients with T2D and either nutritional risk or malnutrition, all of whom are prescribed a diabetes-specific ONS. 7. Collected Variables Sociodemographic: age, sex, education level, etc. Clinical and anthropometric: weight, muscle mass, comorbidities. ONS-related: product name, dosage, duration, modifications, palatability. Nutritional requirements: daily caloric, protein, fat, and carbohydrate needs. Healthcare resource utilization: hospital admissions, emergency visits, specialist consultations, and diabetes medication adjustments. Metabolic profile: HbA1c, fasting glucose, lipid panel, albumin, total protein, hemoglobin, liver enzymes, eGFR, and CRP. Functional assessment: SARC-F scale, handgrip strength, bioelectrical impedance analysis (BIA), nutritional ultrasound, and Timed Up and Go test. Patient-reported outcomes: NutriQoL® quality-of-life questionnaire, satisfaction survey, treatment adherence questionnaire, and ONS palatability scale. 8. Data Management and Analysis Data will be managed by Outcomes'10 and analyzed using STATA v.14. Descriptive and comparative analyses will be conducted to address the primary and secondary objectives. All data will be reviewed and pseudonymized to ensure patient confidentiality.
Study Type
OBSERVATIONAL
Enrollment
334
Hospital Universitario Marqués de Valdecilla
Santander, Cantabria, Spain
RECRUITINGHospital Universitario Juan Ramón Jiménez
Huelva, Huelva, Spain
RECRUITINGHospital UniversitarioDoctor Negrín
Las Palmas de Gran Canaria, Las Palmas, Spain
RECRUITINGHospital La Princesa
Madrid, Madrid, Spain
RECRUITINGHospital Clínico San Carlos
Madrid, Madrid, Spain
RECRUITINGHospital Universitario La Paz
Madrid, Madrid, Spain
RECRUITINGHospital Virgen de la Victoria
Málaga, Malaga, Spain
RECRUITINGHospital Universitario Central de Asturias
Oviedo, Principality of Asturias, Spain
RECRUITINGHospital Universitario Virgen del Rocío
Seville, Sevilla, Spain
RECRUITINGHospital Universitario Virgen de la Macarena
Seville, Sevilla, Spain
RECRUITING...and 2 more locations
Descriptive of study population
Descriptive information of the population at V1
Time frame: Baseline visit (V1)
Percentage change of blood test parameters
Changes in blood test measures will be compared
Time frame: From enrollment to end of treatment at 24 weeks
Percentage of patients with improvement in the nutritional status
Changes in GLIM or MUST classifications
Time frame: From enrollment to end of treatment at 24 weeks
Associated cost at 6-month follow-up
They will be estimated by multiplying the number of units used by their unit cost (derived from eSalud and Botplus databases). Unit: Number of events; euros (€)
Time frame: From enrollment to end of treatment at 24 weeks
Adherence with prescribed oral nutritional supplement (ONS)
Participants will be categorized as compliant (≥80% consumption) or non-compliant (\<80%).
Time frame: From enrollment to end of treatment at 24 weeks
Change in functional status of participants over time
Changes between visits in SARC-F scale categories
Time frame: From enrollment to end of treatment at 24 weeks
Change in NutriQoL® quality-of-life score
Patients will be classified according to a quality-of-life category (excellent, good, acceptable, poor, very poor). Test total scoring values.
Time frame: From enrollment to end of treatment at 24 weeks
Patient satisfaction of the ONS product at 6 months
Responses to the satisfaction questionnaires will be summarized as number and percentage of participants selecting each category at V3.
Time frame: From enrollment to end of treatment at 24 weeks
Patient palatability of the ONS product at 6 months
Responses to the palatability questionnaires will be summarized as number and percentage of participants selecting each category at V3.
Time frame: From enrollment to end of treatment at 24 weeks
Health resource use
Frequencies of treatment changes, administration route, specialist consultations, and hospitalizations will be recorded and quantitative variables (treatment dose, treatment duration, number and days of hospitalization, consultations) will be summarized using mean ± SD.
Time frame: From enrollment to end of treatment at 24 weeks
Change in nutritional status
It will be estimated according to GLIM or MUST classification
Time frame: From enrollment to end of treatment at 24 weeks
Percentage change in BMI
Weight and height will be combined to report BMI in kg/m2
Time frame: From enrollment to end of treatment at 24 weeks
Maximum prehensile strenght value
Probe: handgrip test by using a hand dynamometer
Time frame: From enrollment to end of treatment at 24 weeks
30" chair test
Test: a patient will have to stand-up and sit-down as maximim number of times in 30", from a chair, with both arms crossed in the chest.
Time frame: From enrollment to end of treatment at 24 weeks
Impedancimetry values
Test: bioimpedance
Time frame: From enrollment to end of treatment at 24 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.